Store-brand Pepcid
This article was originally published in The Tan Sheet
Executive Summary
FDA approves abbreviated new drug applications from Perrigo and Leiner Health Products' development partner, Dr. Reddy's Laboratories, for OTC versions of famotidine 20 mg acid indigestion treatment (Johnson & Johnson-Merck's Pepcid AC). The FDA approval on Sept. 25 for private label versions of the heartburn drug comes two days after Merck's exclusivity for the product expired. Both companies began shipping the product to retail outlets immediately following the approvals. Annual Pepcid AC sales total approximately $60 mil., according to Perrigo...
You may also be interested in...
Patent Case Ruling Allows For Launch Of Generic Pepcid Complete
The U.S. District Court for the Southern District of New York invalidated a key patent for Johnson & Johnson/Merck's Pepcid Complete, opening the door for Perrigo to enter the market with a private-label equivalent
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.